ID

38233

Descrizione

Tesetaxel as First-line Therapy for Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01221870

collegamento

https://clinicaltrials.gov/show/NCT01221870

Keywords

versioni (1)
  1. 30/09/19 30/09/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

30 settembre 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Breast Neoplasm NCT01221870

Inglese

Eligibility Breast Neoplasm NCT01221870

1 moduli  
Criteria
Descrizione

Criteria

female
Descrizione

Gender

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0079399
at least 18 years of age
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
histologically or cytologically confirmed adenocarcinoma of the breast
Descrizione

Breast adenocarcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0858252
stage iv disease
Descrizione

Disease TNM Breast tumor staging

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0474926
her2 status negative
Descrizione

HER2 Negative

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348908
measurable disease (revised recist; version 1.1)
Descrizione

Measurable Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1513041
eastern cooperative oncology group performance status 0 or 1
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy of at least 3 months
Descrizione

Life Expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
chemotherapy naïve or 1 prior chemotherapy regimen in the adjuvant setting (prior taxane-based adjuvant therapy allowed provided patient had a disease-free interval of at least 12 months after completing this adjuvant therapy)
Descrizione

Chemotherapy Absent | Prior Chemotherapy Adjuvant | taxane | Interval Disease Free Duration | Status post Adjuvant therapy Completion

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C1514457
UMLS CUI [2,2]
C1522673
UMLS CUI [3]
C0215136
UMLS CUI [4,1]
C1272706
UMLS CUI [4,2]
C0012634
UMLS CUI [4,3]
C0332296
UMLS CUI [4,4]
C0449238
UMLS CUI [5,1]
C0231290
UMLS CUI [5,2]
C0677850
UMLS CUI [5,3]
C0205197
prior hormonal therapy, aromatase inhibitor therapy, and immunotherapy allowed
Descrizione

Prior Hormone Therapy | Aromatase Inhibitors | Prior Immunotherapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1514460
UMLS CUI [2]
C0593802
UMLS CUI [3]
C1514461
prior radiotherapy in the adjuvant setting allowed provided that less than 25% of the bone marrow had been irradiated
Descrizione

Prior radiation therapy Adjuvant Bone Marrow Percentage

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C1522673
UMLS CUI [1,3]
C0005953
UMLS CUI [1,4]
C0439165
adequate bone marrow, hepatic, and renal function, as specified in the protocol
Descrizione

Bone Marrow function | Liver function | Renal function

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
at least 4 weeks and recovery from effects of prior surgery, hormonal therapy, aromatase inhibitor therapy, immunotherapy, radiotherapy, or other therapy with an approved or investigational agent
Descrizione

Effects of Prior Therapy Patient recovered | Operative Surgical Procedures | Prior Hormone Therapy | Aromatase Inhibitors | Prior Immunotherapy | Prior radiation therapy | Pharmacotherapy | Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1704420
UMLS CUI [1,2]
C1514463
UMLS CUI [1,3]
C1115804
UMLS CUI [2]
C0543467
UMLS CUI [3]
C1514460
UMLS CUI [4]
C0593802
UMLS CUI [5]
C1514461
UMLS CUI [6]
C0279134
UMLS CUI [7]
C0013216
UMLS CUI [8]
C0013230
ability to swallow an oral solid-dosage form of medication
Descrizione

Able to swallow Oral medication Solid Dose Form

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2712086
UMLS CUI [1,2]
C0175795
UMLS CUI [1,3]
C1378566
primary exclusion criteria:
Descrizione

Exclusion Criteria Primary

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0205225
known metastasis to the central nervous system
Descrizione

CNS metastases

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0686377
history of other malignancy within the last 5 years other than curatively treated basal and squamous cell carcinoma of the skin or carcinoma of the cervix in situ
Descrizione

Cancer Other | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Squamous cell carcinoma of skin | Exception Curative treatment Carcinoma in situ of uterine cervix

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1273390
UMLS CUI [2,3]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1273390
UMLS CUI [3,3]
C0553723
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1273390
UMLS CUI [4,3]
C0851140
significant medical disease other than stage iv breast cancer
Descrizione

Disease Significant | Exception Secondary malignant neoplasm of female breast

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0750502
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0346993
presence of neuropathy > grade 1 (nci ctc, version 4.0)
Descrizione

Neuropathy CTCAE Grades

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0442874
UMLS CUI [1,2]
C1516728
history of hypersensitivity to a taxane
Descrizione

Hypersensitivity Taxane

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0215136
need to continue any regularly-taken medication that is a potent inhibitor or inducer of the cyp3a pathway or p-glycoprotein activity
Descrizione

CYP3A Inhibitors | CYP3A Inducers | P-Glycoprotein Inhibitors | P-Glycoprotein Activity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3850056
UMLS CUI [2]
C3850044
UMLS CUI [3]
C3500483
UMLS CUI [4]
C1753353
Ritorna all'inizio della pagina

Similar models

Eligibility Breast Neoplasm NCT01221870

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Age
Item
at least 18 years of age
boolean
C0001779 (UMLS CUI [1])
Breast adenocarcinoma
Item
histologically or cytologically confirmed adenocarcinoma of the breast
boolean
C0858252 (UMLS CUI [1])
Disease TNM Breast tumor staging
Item
stage iv disease
boolean
C0012634 (UMLS CUI [1,1])
C0474926 (UMLS CUI [1,2])
HER2 Negative
Item
her2 status negative
boolean
C2348908 (UMLS CUI [1])
Measurable Disease
Item
measurable disease (revised recist; version 1.1)
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group performance status 0 or 1
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of at least 3 months
boolean
C0023671 (UMLS CUI [1])
Chemotherapy Absent | Prior Chemotherapy Adjuvant | taxane | Interval Disease Free Duration | Status post Adjuvant therapy Completion
Item
chemotherapy naïve or 1 prior chemotherapy regimen in the adjuvant setting (prior taxane-based adjuvant therapy allowed provided patient had a disease-free interval of at least 12 months after completing this adjuvant therapy)
boolean
C0392920 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C1514457 (UMLS CUI [2,1])
C1522673 (UMLS CUI [2,2])
C0215136 (UMLS CUI [3])
C1272706 (UMLS CUI [4,1])
C0012634 (UMLS CUI [4,2])
C0332296 (UMLS CUI [4,3])
C0449238 (UMLS CUI [4,4])
C0231290 (UMLS CUI [5,1])
C0677850 (UMLS CUI [5,2])
C0205197 (UMLS CUI [5,3])
Prior Hormone Therapy | Aromatase Inhibitors | Prior Immunotherapy
Item
prior hormonal therapy, aromatase inhibitor therapy, and immunotherapy allowed
boolean
C1514460 (UMLS CUI [1])
C0593802 (UMLS CUI [2])
C1514461 (UMLS CUI [3])
Prior radiation therapy Adjuvant Bone Marrow Percentage
Item
prior radiotherapy in the adjuvant setting allowed provided that less than 25% of the bone marrow had been irradiated
boolean
C0279134 (UMLS CUI [1,1])
C1522673 (UMLS CUI [1,2])
C0005953 (UMLS CUI [1,3])
C0439165 (UMLS CUI [1,4])
Bone Marrow function | Liver function | Renal function
Item
adequate bone marrow, hepatic, and renal function, as specified in the protocol
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Effects of Prior Therapy Patient recovered | Operative Surgical Procedures | Prior Hormone Therapy | Aromatase Inhibitors | Prior Immunotherapy | Prior radiation therapy | Pharmacotherapy | Investigational New Drugs
Item
at least 4 weeks and recovery from effects of prior surgery, hormonal therapy, aromatase inhibitor therapy, immunotherapy, radiotherapy, or other therapy with an approved or investigational agent
boolean
C1704420 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
C1115804 (UMLS CUI [1,3])
C0543467 (UMLS CUI [2])
C1514460 (UMLS CUI [3])
C0593802 (UMLS CUI [4])
C1514461 (UMLS CUI [5])
C0279134 (UMLS CUI [6])
C0013216 (UMLS CUI [7])
C0013230 (UMLS CUI [8])
Able to swallow Oral medication Solid Dose Form
Item
ability to swallow an oral solid-dosage form of medication
boolean
C2712086 (UMLS CUI [1,1])
C0175795 (UMLS CUI [1,2])
C1378566 (UMLS CUI [1,3])
Exclusion Criteria Primary
Item
primary exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
CNS metastases
Item
known metastasis to the central nervous system
boolean
C0686377 (UMLS CUI [1])
Cancer Other | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Squamous cell carcinoma of skin | Exception Curative treatment Carcinoma in situ of uterine cervix
Item
history of other malignancy within the last 5 years other than curatively treated basal and squamous cell carcinoma of the skin or carcinoma of the cervix in situ
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1273390 (UMLS CUI [2,2])
C0007117 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
C0553723 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C1273390 (UMLS CUI [4,2])
C0851140 (UMLS CUI [4,3])
Disease Significant | Exception Secondary malignant neoplasm of female breast
Item
significant medical disease other than stage iv breast cancer
boolean
C0012634 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0346993 (UMLS CUI [2,2])
Neuropathy CTCAE Grades
Item
presence of neuropathy > grade 1 (nci ctc, version 4.0)
boolean
C0442874 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Hypersensitivity Taxane
Item
history of hypersensitivity to a taxane
boolean
C0020517 (UMLS CUI [1,1])
C0215136 (UMLS CUI [1,2])
CYP3A Inhibitors | CYP3A Inducers | P-Glycoprotein Inhibitors | P-Glycoprotein Activity
Item
need to continue any regularly-taken medication that is a potent inhibitor or inducer of the cyp3a pathway or p-glycoprotein activity
boolean
C3850056 (UMLS CUI [1])
C3850044 (UMLS CUI [2])
C3500483 (UMLS CUI [3])
C1753353 (UMLS CUI [4])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial